HomeCompareGULRF vs PFE

GULRF vs PFE: Dividend Comparison 2026

GULRF yields 5.54% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $28.9K in total portfolio value· pulled ahead in Year 9
10 years
GULRF
GULRF
● Live price
5.54%
Share price
$8.34
Annual div
$0.46
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$0.57
Full GULRF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GULRF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGULRFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GULRF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GULRF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GULRF
Annual income on $10K today (after 15% tax)
$471.17/yr
After 10yr DRIP, annual income (after tax)
$0.48/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,319.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GULRF + PFE for your $10,000?

GULRF: 50%PFE: 50%
100% PFE50/50100% GULRF
Portfolio after 10yr
$35.1K
Annual income
$13,129.64/yr
Blended yield
37.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GULRF
No analyst data
Altman Z
1.8
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GULRF buys
0
PFE buys
0
No recent congressional trades found for GULRF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGULRFPFE
Forward yield5.54%6.13%
Annual dividend / share$0.46$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$20.6K$49.6K
Annual income after 10y$0.57$26,258.71
Total dividends collected$563.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GULRF vs PFE ($10,000, DRIP)

YearGULRF PortfolioGULRF Income/yrPFE PortfolioPFE Income/yrGap
1$10,977$277.16$9,153$693.39+$1.8KGULRF
2$11,888$142.17$8,593$849.25+$3.3KGULRF
3$12,792$71.94$8,336$1,066.78+$4.5KGULRF
4$13,723$36.18$8,437$1,384.80+$5.3KGULRF
5$14,702$18.14$9,013$1,875.40+$5.7KGULRF
6$15,740$9.08$10,306$2,680.72+$5.4KGULRF
7$16,847$4.54$12,820$4,101.38+$4.0KGULRF
8$18,028$2.27$17,673$6,826.70+$355.00GULRF
9← crossover$19,291$1.14$27,543$12,591.86$8.3KPFE
10$20,642$0.57$49,560$26,258.71$28.9KPFE

GULRF vs PFE: Complete Analysis 2026

GULRFStock

Guoco Group Limited, an investment holding company, engages in the principal investment, property investment and development, hospitality and leisure, and financial service businesses. The company's Principal Investment segment offers debt, equity, and direct investments, as well as treasury operations with trading and strategic investments in global capital markets. Its Property Development and Investment segment develops residential and commercial properties, as well as holds properties for rental income in Singapore, China, Malaysia, Vietnam, and Hong Kong. The company's Hospitality and Leisure Business segment owns, leases, and manages hotels; and operates gaming and leisure businesses in the United Kingdom, Spain, and Belgium. This segment owns and operates hotels under Guoman, Thistle, and Thistle Express brands, as well as operates Hard Rock Hotel London under a third party brand. It offers Mecca, a bingo operator in Great Britain with 125 venues and a digital channel, www.meccabingo.com that provides a selection of games from bingo to slot machines; Grosvenor Casinos, a casino operator with 70 casinos in Great Britain and casino in Belgium, as well as its digital channel, www.grosvenorcasinos.com; and Enracha, which offers a range of popular games and sports betting through its 10 venues in Spain and its digital channels www.enracha.es, www.yobingo.es, and www.yocasino.es. Its Financial Services segment provides commercial and consumer, Islamic, and investment banking services; and life and general insurance, Takaful insurance, fund management and unit trust, corporate advisory, and stock broking services. The company also offers royalty entitlement of Bass Strait's oil and gas production, as well as manufactures, markets, and distributes health products. The company is based in Central, Hong Kong. Guoco Group Limited is a subsidiary of GuoLine Overseas Limited.

Full GULRF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GULRF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GULRF vs SCHDGULRF vs JEPIGULRF vs OGULRF vs KOGULRF vs MAINGULRF vs JNJGULRF vs MRKGULRF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.